MEDIPHARM LABS CORP (LABS.CA) Stock Analyst Ratings
Canada - TSX:LABS - CA58504D1006 - Common Stock
0.065 CAD
-0.01 (-7.14%)
ChartMill assigns a Buy % Consensus number of 42% to LABS.CA. The Buy consensus is the weighted average rating of the current analysts ratings.
LABS.CA was analyzed by 9 analysts. The buy percentage consensus is at 42. So analysts seem to be rather negative about LABS.CA.
In the previous month the buy percentage consensus was at a similar level.
LABS.CA was analyzed by 9 analysts. More opinions would make the average more meaningful.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-04-04 | Canaccord Capital | Downgrade | Hold |
| 2022-04-04 | Alliance Global Partners | Downgrade | Buy |
| 2021-11-16 | CanaccordFinancial | Downgrade | Hold |
| 2021-08-17 | Alliance Global Partners | Downgrade | Strong Buy |
| 2021-08-17 | Canaccord Genuity | Downgrade | Buy |
MEDIPHARM LABS CORP / LABS.CA FAQ
What is the consensus rating for LABS stock?
The consensus rating for MEDIPHARM LABS CORP (LABS.CA) is 42.2222 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
How many analysts cover MEDIPHARM LABS CORP (LABS.CA) stock?
The number of analysts covering MEDIPHARM LABS CORP (LABS.CA) is 9.